Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Nephrotoxicity is the most troublesome side effect of cyclosporin A (CSA) therapy. In vitro studies have shown that verapamil and PGE analogues can protect human and rat kidney allografts and murine pancreatic B cells from CSA cytotoxicity. The LLC-PK.1 pig kidney cell line has recently been shown to be a use-ful in vitro model system for studying CSA nephrotoxicity. We have adopted the MTT assay to assess the effects of CSA on LCC-PK.1 cell growth and have examined the effects of verapamil and MDL 646, a cyto-protective PGE1 analogue, on CSA nephrotoxicity. The results show that neither compound prevents the cytotoxic effects of CSA on kidney cells.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!